Evidence map›Paper›PMID 41304988›Full record

ArticlePharmaceuticals (Basel, Switzerland)2025

Effect of Nano-Gefitinib on Solid Ehrlich Carcinoma via Targeting EGFR, RIPK2 Pathways, and Macrophage Reprogramming.

Neveen R Ashoura, Hebatallah M Saad, Enas I El Zahaby, Alyaa R Salama, Nihal E Amer, Omnya Elhussieny, Hanan A Edres, Hisham A Nematalla, Salman A A Mohammed

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Neveen R AshouraDepartment of Pharmacology, Faculty of Veterinary Medicine, Alexandria University, Alexandria 21944, Egypt.ORCID 0000-0001-8615-6417
Hebatallah M SaadDepartment of Pathology, Faculty of Veterinary Medicine, Matrouh University, Marsa Matrouh 51744, Egypt.ORCID 0000-0001-9555-7300
Enas I El ZahabyDepartment of Pharmaceutics, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 35712, Egypt.ORCID 0000-0002-1322-8309
Alyaa R SalamaDepartment of Pathology, Faculty of Veterinary Medicine, Alexandria University, Alexandria 21944, Egypt.ORCID 0009-0004-2822-6674
Nihal E AmerBenha University Hospital, Benha University, Benha 13518, Egypt.
Omnya ElhussienyDepartment of Histology and Cytology, Faculty of Veterinary Medicine, Matrouh University, Marsa Matrouh 51744, Egypt.ORCID 0000-0001-6351-594X
Hanan A EdresDepartment of Biochemistry, Faculty of Veterinary Medicine, Alexandria University, Alexandria 21944, Egypt.
Hisham A NematallaDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Damanhour University, Damanhour 22514, Egypt.ORCID 0000-0002-7218-4115
Salman A A MohammedDepartment of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Buraydah 51452, Saudi Arabia.ORCID 0000-0002-9250-100X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

antineoplastic activityantioxidant activityapoptosiscancerEhrlichgefitinib nanoparticlesmacrophage reprogrammingoxidative stress

Identifiers

PMID41304988
PMCPMC12655097

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.